

THE ROLE OF THE MUCINOUS COMPONENT AS AN INDEPENDENT PREDICTIVE FACTOR IN COLORECTAL ADENOCARCINOMA THERAPY - THE POTENTIAL OF ARTIFICIAL INTELLIGENCE AS AN ADJUNCT TOOL TO IMPROVE TREATMENT OUTCOMES

Milina Srđan,¹ **Nikolić Marija**,¹ Trifunović Nemanja,¹ Trifunović Jovana,² Surla Dimitrije¹

¹ Clinical Hospital Center Zemun, Department of General Surgery, Belgrade, Serbia

² Clinical Hospital Center Zemun, Oncology Hospital, Belgrade, Serbia

Primljen/Received: 01. 07. 2025.

Prihvaćen/Accepted: 09. 08. 2025.

Online First: August 2025.

Abstract: Mucinous adenocarcinoma of the colon (MAC) is a distinct histological subtype of colorectal cancer (CRC), defined by the presence of $\geq 50\%$ extracellular mucin. This CRC subtype exhibits unique clinical and molecular characteristics, including more frequent localization in the right colon, higher prevalence among younger patients, and associations with microsatellite instability-high (MSI-H) and BRAF gene mutations. Evidence suggests that MAC demonstrates a poorer response to conventional therapies; however, the independent prognostic value of the mucinous component remains unclear.

This narrative review aims to evaluate the prognostic significance of the mucinous component in CRC. Twenty relevant studies published between 2018 and 2025 were analyzed. Results indicate that MAC is more often detected at advanced stages and shows a weaker response to fluorouracil-based regimens and neoadjuvant chemoradiotherapy in rectal tumors. Nonetheless, several studies reported no significant difference in overall survival between mucinous and non-mucinous carcinomas. Additionally, immune-related factors such as tumor-infiltrating lymphocytes (TILs) and desmoplasia are gaining importance and may have greater prognostic value than mucinous differentiation itself.

MAC also frequently exhibits marked molecular heterogeneity, complicating prognosis and treatment decisions. Consequently, careful patient monitoring and timely molecular profiling are essential for optimizing therapy. Novel artificial intelligence-based models that integrate histological images, molecular biomarkers, and clinical data show promise for personalizing treatment in MAC.

In conclusion, although MAC is currently treated according to standard CRC guidelines, its distinct features underscore the need for individualized therapeutic approaches and further clinical research.

Keywords: mucinous adenocarcinoma, colorectal cancer, prognosis, MSI-H, treatment response.

INTRODUCTION

Colorectal cancer (CRC) is among the leading causes of cancer incidence and mortality worldwide, particularly in countries with medium to high socioeconomic status. Mucinous adenocarcinoma of the colon (MAC) is a distinct histological subtype of CRC, defined by the presence of $\geq 50\%$ extracellular mucin within the tumor. This subtype is characterized by specific features, including preferential localization in the right colon, higher prevalence among younger patients, high microsatellite instability (MSI-H), BRAF gene mutations, and a generally poorer response to therapy, especially fluorouracil-based chemotherapy (1).

In contrast to non-mucinous adenocarcinomas, which often show different biological behavior and clinical outcomes, mucinous adenocarcinomas exhibit notable heterogeneity and distinct patterns of invasion and metastasis. However, the independent prognostic significance of the mucinous component remains a subject of ongoing debate.

The aim of this paper is to explore the prognostic potential of the mucinous component in colon adenocarcinoma through a narrative review of recent literature and to evaluate its clinical relevance.

Histopathological and Molecular Characteristics of Mucinous Adenocarcinoma

Mucinous adenocarcinoma of the colon (MAC) represents a histologically distinct and biologically unique subgroup of colorectal cancer (CRC), with its presence significantly influencing clinical presentation, therapeutic response, and disease outcomes. Defined by the presence of $\geq 50\%$ extracellular mucin in tumor tissue, MAC encompasses a complex biological background beyond its histological classification.

Numerous studies suggest that MAC is not simply a histological variant but a tumor type marked by a distinct molecular profile and immune microenvironment, which poses challenges for standard treatment protocols and raises important questions about its independent prognostic value.

Epidemiological data indicate that MAC occurs more frequently in the right colon and among younger patients, often diagnosed at advanced stages (2–5). Analyses of the SEER database confirm that mucinous tumors are more commonly identified at stages III and IV, reflecting their aggressive clinical behavior (3, 5). Additionally, MAC is more frequently associated with high microsatellite instability (MSI-H) and BRAF mutations, which contribute to its biological uniqueness and have important therapeutic implications (1, 6).

However, the molecular heterogeneity within MAC raises the question of whether all mucinous adenocarcinomas should be regarded as a single homogeneous group.

Immune Microenvironment and Prognostic Indicators

Beyond molecular factors, the immune landscape of MAC has attracted increasing attention. Tumor-infiltrating lymphocytes (TILs) hold particular prognostic significance as strong predictors of survival. Fadel et al. emphasize that the density of lymphocytic infiltration and the presence of desmoplasia have greater predictive value for survival than mucinous differentiation alone (3). High lymphocyte density correlates with a more robust immune response and better prognosis, whereas desmoplasia — reactive fibrous proliferation surrounding the tumor — is linked to a more aggressive disease phenotype and poorer outcome.

Kepil et al. thoroughly characterized the immune phenotype of mucinous tumors, highlighting significant differences in the expression of immune markers (PD-L1, CD8+ T-cells, macrophages CD68 and CD163) compared to non-mucinous tumors (7). These alterations suggest distinct immune evasion mechanisms and potentially differential responses to immunotherapy. Methodologically, the study employed im-

munohistochemistry to precisely localize and quantify these markers, contributing to the reliability of findings and advancing understanding of the mucinous tumor microenvironment.

Controversies in Prognosis and Therapeutic Implications

Prognostic data for MAC remain heterogeneous. Kim et al. reported poorer prognosis and diminished response to adjuvant chemotherapy in stages II and III compared to non-mucinous tumors (4). Conversely, Huang et al. and Dai et al. found no significant differences in outcomes at earlier disease stages (8, 9). These findings suggest that mucinous histology alone is insufficient as an independent prognostic factor, underscoring the need to integrate molecular, histological, and immune parameters.

Chemotherapy Resistance and Limitations of Standard Treatment

Therapeutic response in MAC further complicates clinical management. Standard CRC regimens include FOLFOX, CAPOX, and FOLFIRI; however, MAC tumors often exhibit resistance to fluorouracil-based therapies, especially those with MSI-H and BRAF mutations (1, 6–11). A meta-analysis by McCawley et al. demonstrated that mucinous rectal adenocarcinoma responds significantly worse to neoadjuvant chemoradiotherapy, evidenced by lower pathological regression, higher rates of positive surgical margins, and inferior overall prognosis compared to non-mucinous tumors (10). These differences are attributed to the unique biological properties and microenvironment of mucinous tumors, highlighting the necessity for individualized therapeutic approaches.

While RAS wild-type status remains a key criterion for selecting patients for anti-EGFR therapy, Moretto et al. showed that the presence of a mucinous component may substantially reduce the efficacy of this treatment even in patients with molecular markers of sensitivity (11). This suggests that tumor histological subtype independently influences therapeutic response, advocating for an integrated approach that incorporates both molecular and histopathological tumor characteristics.

Secondary Tumor Risk and Surveillance Considerations

Wu et al. analyzed the risk of secondary malignancies in patients with various CRC histological subtypes, including MAC, and identified specific patterns of new tumor development with elevated risks for certain secondary primary tumors (12). These findings emphasize the need for vigilant long-term follow-up and consideration of histological subtype in secondary prevention strategies.

Emerging Role of Immunotherapy in MSI-H Mucinous CRC

Immunotherapy, particularly anti-PD-1 blockade, shows significant promise in MSI-H mucinous carcinomas, offering novel treatment options for this subgroup characterized by poor chemotherapy response. Interest in applying artificial intelligence (AI) and radiomics for personalized therapy is rapidly increasing, as these approaches enable integration of multidimensional data and more precise prediction of therapeutic outcomes.

Radiomics and Artificial Intelligence in Precision Oncology

Radiomics—the quantitative analysis of medical imaging data (CT, MRI)—combined with AI facilitates prediction of tumor molecular features (KRAS, NRAS, BRAF mutations) and assessment of treatment response. Yang et al. successfully predicted these mutations using CT-based radiomics (13). Shaish et al. demonstrated that MRI-radiomics can predict response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (14). Li et al. developed machine learning models to preoperatively predict perineural invasion and KRAS mutation, with direct clinical applications (15). Within the ATTRACT study, Caruso et al. applied radiogenomics to identify high-risk colorectal tumors, paving the way for integrated strategies to detect biologically aggressive MACs (16, 17). Golia Pernicka et al. showed that MSI status can be predicted using radiomics from baseline CT scans (18), while Abbaspour et al. successfully predicted lymph node metastasis preoperatively with radiomics (19).

Although these data confirm the considerable potential of radiomics and AI in optimizing MAC therapy, widespread clinical implementation requires further research, methodological standardization, and validation through prospective multicenter studies.

CONCLUSION

Mucinous adenocarcinoma of the colon represents a biologically and clinically distinct subgroup of colorectal cancer, characterized by unique molecular, histological, and immunological features that significantly influence therapeutic response and potentially impact patient survival. Although multiple studies have reported a poorer prognosis associated with MAC, especially in advanced disease stages, the prognostic value of the mucinous component alone remains controversial and appears to be modulated by additional factors such as molecular alterations and the tumor immune microenvironment.

The integration of molecular biomarkers—including MSI status, BRAF and RAS mutations—with

immune indicators like tumor-infiltrating lymphocytes and immune checkpoint expression offers a promising avenue for personalizing therapeutic strategies in this subgroup. Moreover, emerging technologies such as radiomics and artificial intelligence hold considerable potential to enhance preoperative tumor characterization, predict treatment response, and refine risk stratification.

To translate these advances into clinical practice, further prospective, multicenter studies are required to validate stratification models and optimize tailored treatment protocols specifically for patients with mucinous adenocarcinoma. Such efforts are essential to improve clinical outcomes and advance precision oncology for this challenging CRC subtype.

Abbreviations

AI – Artificial Intelligence

CAPOX – Capecitabine and Oxaliplatin

CRC – Colorectal Cancer

CT – Computed Tomography

EGFR – Epidermal Growth Factor Receptor

FOLFIRI – 5-Fluorouracil, Leucovorin, and Irinotecan

FOLFOX – 5-Fluorouracil, Leucovorin, and Oxaliplatin

MAC – Mucinous Adenocarcinoma of the Colon

MRI – Magnetic Resonance Imaging

MSI-H – Microsatellite Instability-High

PD-1 – Programmed Cell Death Protein 1

PD-L1 – Programmed Death-Ligand 1

RAS – Rat Sarcoma Viral Oncogene Homolog

SEER – Surveillance, Epidemiology, and End Results (database)

TILs – Tumor-Infiltrating Lymphocytes

Conflict of Interest Statement

The authors declare that there is no conflict of interest related to this study.

Funding: None.

Author Contributions & Responsibilities: The authors take full responsibility for the accuracy and integrity of the content, as well as the validity of institutional affiliations. The publisher remains neutral regarding jurisdictional claims in institutional affiliations. All authors have read and agreed to the published version of the manuscript. All authors contributed equally to the preparation of this manuscript.

Note: Artificial intelligence was not utilized as a tool in this study.

Licensing: This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.

Sažetak**ULOGA MUCINOZNE KOMPONENTE KAO NEZAVISNOG PREDIKTIVNOG FAKTORA U TERAPIJI ADENOKARCINOMA KOLONA-POTENCIJAL VEŠTAČKE INTELIGENCIJE KAO POMOĆNOG ALATA ZA UNAPREĐENJE ISHODA LEČENJA**Milina Srđan,¹ **Nikolić Marija**,¹ Trifunović Nemanja,¹ Trifunović Jovana,² Surla Dimitrije¹¹ Kliničko-bolnički centar Zemun, Služba opšte hirurgije, Beograd, Srbija² Kliničko-bolnički centar Zemun, Bolnica za onkologiju, Beograd, Srbija

Mucinozni adenokarcinom kolona (MAC) je posebna histološka varijanta kolorektalnog karcinoma (CRC), definisana prisustvom $\geq 50\%$ ekstracelularnog mucina. Ovaj podtip CRC-a ima različite kliničke i molekularne karakteristike, kao što su češća lokalizacija u desnom kolonu, viša prevalencija kod mlađih pacijenata, prisustvo mikrosatelitske nestabilnosti (MSI-H), kao i mutacije u BRAF genu. Postoje indicije da MAC pokazuje slabiji odgovor na konvencionalne terapije, ali ostaje pitanje da li mucinozna komponenta ima nezavisan prognostički značaj.

U ovom radu prikazan je narativni pregled literature sa ciljem procene prognostičke vrednosti mucinozne komponente kod CRC. U analizu je uključeno 20 relevantnih studija objavljenih u periodu od 2018. do 2025. godine. Rezultati ukazuju da MAC češće biva otkriven u uznapredovalim stadijumima bolesti i pokazuje slabiji odgovor na fluorouracil-bazirane protokole i neoadjuvantnu radiohemoterapiju kod rektalnih tumora. Ipak, nekoliko studija nije pronašlo značajnu

razliku u ukupnom preživljavanju između mucinoznih i nemucinoznih karcinoma. Pored toga, sve veći značaj imaju imunološki faktori kao što su prisustvo TILs i desmoplazije, koji mogu nadmašiti prognostički uticaj same mucinozne diferencijacije.

Zapaženo je i da MAC često pokazuje izraženu molekularnu heterogenost, što dodatno komplikuje prognozu i terapijski pristup. U tom kontekstu, pažljivo praćenje bolesnika i pravovremena molekularna karakterizacija postaju od ključnog značaja za optimalno lečenje. Novi modeli zasnovani na veštačkoj inteligenciji, koji integrišu histološke slike, molekularne biomarkere i kliničke podatke, ukazuju na potencijal u personalizaciji terapije za MAC. U zaključku, iako se MAC leči prema važećim CRC smernicama, njegove specifičnosti ukazuju na potrebu za individualizovanim terapijskim pristupom i daljim kliničkim istraživanjima.

Cljučne reči: mucinozni adenokarcinom, kolorektalni karcinom, prognoza, MSI-H, terapijski odgovor.

REFERENCES

1. Reynolds IS, O'Connell E, Fichtner M, McNamara DA, Kay EW, Prehn JHM, et al. Mucinous adenocarcinoma of the colon and rectum: a genomic analysis. *J Surg Oncol*. 2019; 120(8): 1427–35. doi: 10.1002/jso.25764.
2. Eunus MF, Saleh FM, Karim SN, Tanzim MA, Hosain MI. Clinicopathological characteristics of mucinous and non-mucinous adenocarcinoma of the colon and rectum. *Myensingh Med J*. 2023; 32(2): 480–6.
3. Fadel MG, Malietzis G, Constantinides V, Pellino G, Tekkis P, Kontovounisios C. Clinicopathological factors and survival outcomes of signet-ring cell and mucinous carcinoma versus adenocarcinoma of the colon and rectum: a systematic review and meta-analysis. *Discov Oncol*. 2021; 12(1): 5. doi: 10.1007/s12672-021-00398-6.
4. Kim S, Huh JW, Lee WY, Yun SH, Kim HC, Cho YB, et al. Prognostic impact of mucinous adenocarcinoma in stage II and III colon cancer. *Dis Colon Rectum*. 2023; 66(11): 1473–80. doi: 10.1097/DCR.0000000000002733.
5. Zhu L, Ling C, Xu T, Zhang J, Zhang Y, Liu Y, et al. Clinicopathological features and survival of signet-ring cell carcinoma and mucinous adenocarcinoma of right colon, left colon, and rectum. *Pathol Oncol Res*. 2021; 27: 1609800. doi: 10.3389/pore.2021.1609800.
6. Reynolds IS, O'Connell E, Fichtner M, Blümel A, Mason SE, Kinross J, et al. An insight into the driver mutations and molecular mechanisms underlying mucinous adenocarcinoma of the rectum. *Dis Colon Rectum*. 2021; 64(6): 677–88. doi: 10.1097/DCR.0000000000001825.
7. Kepil N, Batur S, Goksel S. Immunohistochemical and genetic features of mucinous and signet-ring cell carcinomas of the stomach, colon and rectum: a comparative study. *Int J Clin Exp Pathol*. 2019; 12(9): 3483–91.
8. Huang L, Luo S, Lai S, Liu Z, Hu H, Chen M, et al. Survival after curative resection for stage I colorectal mucinous adenocarcinoma. *BMC Gastroenterol*. 2022; 22(1): 192. doi: 10.1186/s12876-022-02276-z.
9. Dai D, Zhou B, Zhong Y, Jin H, Wang X. Survival of patients with resected primary colorectal mucinous adenocarcinoma: A competing risk nomogram analysis. *Oncol Lett*. 2019; 18(6): 6594–604. doi: 10.3892/ol.2019.11024.
10. McCawley N, Clancy C, O'Neill BD, Deasy J, McNamara DA, Burke JP. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. *Dis Colon Rectum*. 2016; 59(12): 1200–8. doi: 10.1097/DCR.0000000000000635.
11. Moretto R, Morano F, Ongaro E, Rossini D, Pietrantonio F, Casagrande M, et al. Lack of benefit from anti-EGFR treatment in RAS and BRAF wild-type metastatic colorec-

tal cancer with mucinous histology or mucinous component. Clin Colorectal Cancer. 2019; 18(2): 116–24. doi: 10.1016/j.clcc.2019.02.007.

12. Wu M, Huang M, He C, Chen C, Li H, Wang J, et al. Risk of second primary malignancies based on the histological subtypes of colorectal cancer. Front Oncol. 2021; 11: 650937. doi: 10.3389/fonc.2021.650937.

13. Yang L, Dong D, Fang M, Zhu Y, Zang Y, Liu Z, et al. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? EurRadiol. 2018; 28(5): 2058–67. doi: 10.1007/s00330-017-5146-8.

14. Shaish H, Aukerman A, Vanguri R, Spinelli A, Armenta P, Jambawalikar S, et al. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study. Eur Radiol. 2020; 30(11): 6263–73. doi: 10.1007/s00330-020-06968-6.

15. Li Y, Eresen A, Shangguan J, Yang J, Benson AB 3rd, Yaghamai V, et al. Preoperative prediction of perineural invasion and KRAS mutation in colon cancer using machine learning. J

Cancer Res Clin Oncol. 2020; 146(12): 3165–74. doi: 10.1007/s00432-020-03354-z.

16. Caruso D, Polici M, Zerunian M, Monterubbiano A, Tarallo M, Pillozzi E, et al. CT-based radiogenomic analysis to predict high-risk colon cancer (ATTRACT): a multicentric trial. Eur Radiol. 2025 Jun 5. doi: 10.1007/s00330-025-11728-5. Online ahead of print.

17. Mei WJ, Mi M, Qian J, Xiao N, Yuan Y, Ding PR. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: a narrative review. Front Immunol. 2022; 13: 1019582. doi:10.3389/fimmu.2022.1019582.

18. Golia Pernicka JS, Gagniere J, Chakraborty J, Yamashita R, Nardo L, Creasy JM, et al. Radiomic-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation. Abdom Radiol (NY). 2019; 44(11): 3755–63. doi: 10.1007/s00261-019-02117-w.

19. Abbaspour E, Karimzadghagh S, Monsef A, Joukar F, Mansour Ghanaei F, Hassanipour S. Application of radiomics for preoperative prediction of lymph node metastasis in colorectal cancer: a systematic review and meta-analysis. Int J Surg. 2024; 110(6): 3795–813. doi: 10.1097/JS9.0000000000001239.

*Accepted papers are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of Sanamed. The final text of the article may be changed before the final publication. Accepted papers can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI. When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

How to cite this article: Milina S, Nikolić M, Trifunović N, Trifunović J, Surla D. The role of the mucinous component as an independent predictive factor in colorectal adenocarcinoma therapy – the potential of artificial intelligence as an adjunct tool to improve treatment outcomes. Sanamed. Online First, August 2025. doi: 10.5937/sanamed0-59880.

Correspondence to/Autor za korespondenciju

Marija Nikolić,
Vukova 9, CHC Zemun, Belgrade, Serbia
Email: marija.nikolic80@gmail.com
phone: +381 64 4139268

ORCID iD:

Marija Nikolić: 0009-0004-3415-1277
Nemanja Trifunović: 0009-0001-1085-9500
Jovana Trifunović: 0009-0005-1373-6521